Is there anyone here with optic neuritis who has noticed any vision improvements after taking Ampyra? I was dx with MS about 5 years ago after going in for vision problems (which ended up being optic neuritis.) My vision has never fully recovered. I think my good eye is at about 20/30 or 40 and the bad one is close to 20/200. Unfortunately my damaged/blind spot is in my central vision in the affected eye. ...

Hi all
I was just wondering is there any natural/homeopathic alternative to ampyra showing reasonable results. Any supplements etc. that have a positive result with stiffness and spasticity? Any recommendations would be gratefully appreciated.

Gymbuff

Acorda Therapeutics, Inc. today announced safety data from more than 62,400 people with multiple sclerosis (MS) taking Ampyra (dalfampridine) Extended Release Tablets, 10 mg during the first two years of availability in the United States. The data showed that the safety profile of Ampyra is similar to that observed in clinical trials.

This analysis was presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held ...

PBS is currently reviewing

http://www.msra.org.au/treatment-improv ... its-scheme.

Comments

http://www.health.gov.au/internet/main/ ... ssion_form

Reply to topic in 'general' section:

I have been using it for about 2 months. It's definitely not a wonder drug. I'm really not sure if I am walking any better - maybe marginally. As that research from squiffy stated, I think I would get more or equal benefit from physio.
I think I might go off it for awhile and compare.
When you have a progressive condition like MS, you get in the habit ...

Drug manufacturer did not present evaluable study data on the appropriate comparator therapy

Fampridine (trade name Fampyra®) has been approved in Germany since July 2011 for adult patients suffering from a higher grade walking disability (grades 4 to 7 on the EDSS disability status scale), as a result of multiple sclerosis (MS). The German Institute for Quality and Efficiency in Health Care (IQWiG) has assessed the added benefit of the drug pursuant to the ...

Acorda's Ampyra fails main goal of post-marketing study

Mon Aug 13, 2012 7:39am EDT
(Reuters) - Acorda Therapeutics Inc said a post-marketing study of its multiple sclerosis drug Ampyra failed to meet the main trial goal of an improvement in patients' walking speed.

The 5 mg and 10 mg doses of Ampyra did not yield statistically significant results on the timed 25-foot walk test as compared with the placebo group, the company said.

...

The U.S. Food and Drug Administration has issued a warning to patients and physicians about the increased risk of seizures in multiple sclerosis patients taking the drug Ampyra.

The drug was developed by Acorda Therapeutics Inc to improve walking ability in patients with multiple sclerosis. Biogen Idec Inc has rights to the drug in Europe where it is sold under the brand name Fampyra.

The FDA said that based on reports, it recently evaluated ...

Antone know the type of UTI Ampyra causes and the preferred antibotic

My wife has been taking Ampyra for 2+ years now and so far it's working great with her balance and coordination.
No side effects. Was taking it in conjunction with Beta Seron but recently dropped Beta for Gilenya.